Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Apr 04, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 4, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR)
Mar 17, 2022
Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion
Mar 11, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a
Mar 10, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 10, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors. “We are delighted to have Ms.
Mar 07, 2022
Data presented at ESMO TAT from Cohort 4 of the ZENITH20 clinical trial met the primary endpoint HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 7, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the
Feb 28, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 28, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer
Feb 11, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 11, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S.
Jan 20, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 20, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the B. Riley Securities 2022 Virtual Oncology Conference .
Jan 05, 2022
Workforce reduction of approximately 30% Cash runway extended into 2023 Resources to be focused on late-stage assets, poziotinib and ROLONTIS ® HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 5, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted
Jan 04, 2022
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 4, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for
Dec 06, 2021
Fast Track application is based on positive data in NSCLC HER2 exon 20 insertion mutations in previously treated patients Positive Results for Cohort 2 of ZENITH20 clinical trial published in Journal of Clinical Oncology HENDERSON, Nev. --(BUSINESS WIRE)--Dec.
Dec 01, 2021
Tom Riga named President and Chief Executive Officer and will join the Board of Directors effective December 31, 2021 Joe Turgeon , President and Chief Executive Officer, to retire and step down from Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 1, 2021-- Spectrum Pharmaceuticals, Inc.
Nov 30, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation
Nov 11, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 11, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference .
Nov 10, 2021
Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact
Nov 03, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 3, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate
Oct 07, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 7, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS
Sep 22, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference .
Sep 18, 2021
Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2021-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Sep 13, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 13, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small
Displaying 21 - 40 of 886